Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP‐DRI‐12-Reference-Cited by-同舟云学术

Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP‐DRI‐12

Published:2022-11-24 Issue:4 Volume:19 Page:2204133
ISSN:1613-6810
Container-title:Small
language:en
Short-container-title:Small

Author:

Wang Liting¹,Fu Hao¹,Song Liwei²,Wu Zhihua³,Yu Jian³,Guo Qianqian¹,Chen Chuanrong³,Yang Xupeng³,Zhang Jiali³,Wang Quan¹,Duan Yourong¹³^ORCID,Yang Yunhai²

Affiliation:

1. State Key Laboratory of Oncogenes and Related Genes Renji Hospital School of Biomedical Engineering Shanghai Jiao Tong University Shanghai 200032 China

2. Shanghai Pulmonary Tumor Medical Center Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai 200080 China

3. State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200032 China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/smll.202204133

Reference63 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

3. Emerging drugs for EGFR-mutated non-small cell lung cancer